Torcetrapib – 50 mg

Brand:
Cayman
CAS:
262352-17-0
Storage:
-20
UN-No:
Non-Hazardous - /

Cholesteryl ester transfer protein (CETP) catalyzes the exchange of cholesteryl esters from high-density lipoprotein (HDL) cholesterol to apolipoprotein B-containing lipoproteins, including very low-density lipoprotein (VLDL) and LDL.{22539} Torcetrapib is an inhibitor of CETP activity (IC50 = 50 nM) that raises HDL cholesterol and reduces LDL cholesterol levels by forming a nonproductive complex between CETP and HDL.{14626} Although torcetrapib produced consistent antiatherogenic effects in rabbits, clinical trials of torcetrapib were terminated early due to deleterious hypertensive effects.{22539, 22538} PDGFR, HGFR (c-Met), IL-2 receptor, and ErbB1- tyrosine kinase have subsequently been identified as direct off-targets of this compound.{22540}  

 

SKU: - Category:

Description

An inhibitor of CETP activity (IC50 = 50 nM) that raises HDL cholesterol and reduces LDL cholesterol levels by blocking CTEP association with HDL


Formal name: 4S-[[[3,5-bis(trifluoromethyl)phenyl]methyl](methoxycarbonyl)amino]-2R-ethyl-3,4-dihydro-6-(trifluoromethyl)-1(2H)-quinolinecarboxylic acid, ethyl ester

Synonyms:  CP 529,414

Molecular weight: 600.5

CAS: 262352-17-0

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Small Molecule Inhibitors||Research Area|Cardiovascular System|Cardiovascular Diseases|Atherosclerosis||Research Area|Cardiovascular System|Lipids & Lipoproteins|Lipoproteins||Research Area|Cardiovascular System|Lipids & Lipoproteins|Storage & Transport